1Scarantino C,LeVeque F,Swann RS,et al.Effect of pilocarpine during radiation therapy:results of RTOG 97-09,a phase Ⅲ randomized study in head and neck cancer patients[J].J Support Oncol,2006,4(5):252-258.
2Nyardy Z,Nemeth A,Ban A,et al.A randomized study to assess the effectiveness of orally administered pilocarpine during and after radiotherapy of head and neck cancer[J].Anticancer Res,2006,26(2B):1557-1562.
3Wasserman TH,Brizel DM,Henke M,et al.Influence of intravenous amifostine on xerostomia,tumor control,and survival after radiotherapy for head-and-neck cancer:2-year follow-up of a prospective,randomized,phase Ⅲ trial[J].Int J Radiat Oncol Biol Phys,2005,63(4):985-990.
4Antonadou D,Pepelassi M,Synodinou M,et al.Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cance[J].Int J Radiat Oncol Biol Phys,2002,52(3):739-747.
5Jellema AP,Slotman BJ,Muller MJ,et al.Radiotherapy alone,versus radiotherapy with amifostine 3 times weekly,versus radiotherapy with amifostine 5 times weekly:A prospective randomized study in squamous cell head and neck cancer[J].Cancer,2006,107(3):544-553.
6Taylor SE.Efficacy and economic evaluation of pilocarpine in treating radiation-induced xerostomia[J].Expert Opin Pharmacother,2003,4(9):1489-1497.
7Padrain W,Julie A.Oralpilocarpine:new preparation,Xerostomia after radiation therapy:moderately effective but costly[J].Prescrire Int,2002,11(60):99-101.
8Nieuw AV,Veerman EC.Current therapies for xerostomia and salivary gland hyporunction associated with cancer therapies[J].Support Care Cancer,2003,11(4):226-231.
9Wijers OB,Levendag PC,Braaksma MM,et al.Patients with head and neck cancer cured by radiation therapy:a survey of the dry mouth syndrome in long-term survivors[J].Head Neck,2002,24(1):737-747.
10Eisbruch A,Ship JA,Kim HM,et al.Partial irradiatinon of the parot id gland[J].Semin Radiat Oncol,2001,11(3):234-239.
7Ish-Shalom S, Durleshter L, Segal E, et al. Sialochemical and oxidative analyses in radioactive ^131Ⅰ-treated patients with thyroid carcinoma. Eur J Endocrino1,2008,158 (5) :677-681.
8Merchant M, Weinberger SR. Recent advancements in surface- enhanced laser desorptiort/ionization -time of flight-mass spectrometry. Electrophoresis,2000,21 (6) : 1164-1167.
9von Eggeling F, Junken K, Feide W, et al. Mass spectrometry meets chip technology:a new proteomic tool in cancer research. Electrophorisis,2001,22 (14) :2898-2902.
10Hasan R, Aakif UK, Abid H, et al. Quantitative evaluation of salivary gland dysfunction after radioiodinet herapy using salibary gland scintigraphy. Nucl Med Commun, 2006,27(6) :495-499.
